The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 17, 2015

Filed:

Jun. 01, 2007
Applicants:

David Monteith, Pittstown, NJ (US);

John O'mullane, Mountain Lakes, NJ (US);

Joseph P. Reo, Lakeland, TN (US);

Robert T. Nowak, New Providence, NJ (US);

Jiansheng Wan, Springfield, NJ (US);

Mohammed A. Kabir, Lakeland, TN (US);

Malaz A. Abutarif, North Brunswick, NJ (US);

Glenn E. Fritz, Arlington, TN (US);

Inventors:

David Monteith, Pittstown, NJ (US);

John O'Mullane, Mountain Lakes, NJ (US);

Joseph P. Reo, Lakeland, TN (US);

Robert T. Nowak, New Providence, NJ (US);

Jiansheng Wan, Springfield, NJ (US);

Mohammed A. Kabir, Lakeland, TN (US);

Malaz A. Abutarif, North Brunswick, NJ (US);

Glenn E. Fritz, Arlington, TN (US);

Assignee:

MSD Consumer Care, Inc., Memphis, TN (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); A61K 31/4545 (2006.01); A61K 9/14 (2006.01); A61P 11/02 (2006.01); A61P 31/16 (2006.01); A61P 37/00 (2006.01); A61K 9/48 (2006.01); A61K 9/22 (2006.01); A61K 9/24 (2006.01); A61K 9/20 (2006.01);
U.S. Cl.
CPC ...
A61K 9/2054 (2013.01); A61K 9/209 (2013.01);
Abstract

The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.


Find Patent Forward Citations

Loading…